T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity

• Published in: Clinical & translational immunology Vol. 10; no. 9; p. e1341
• Main Authors: Casado, Jose L, Haemmerle, Johannes, Vizcarra, Pilar, Rodriguez-Dominguez, Mario, Velasco, Tamara, Velasco, Hector, Centenera, Elena, Romero-Hernandez, Beatriz, Fernandez-Escribano, Marina, Vallejo, Alejandro
• Format: Journal Article
• Language: English
• Published: Australia John Wiley & Sons, Inc 01.01.2021; John Wiley and Sons Inc; Wiley
• Subjects: Antibodies; Antibody response; Cell-mediated immunity; cellular immunity; Coronaviruses; COVID-19; COVID-19 vaccines; cross‐reactivity; Humoral immunity; Immunoglobulin G; Infections; Lymphocytes; Lymphocytes T; Medical personnel; mRNA vaccine; mRNA vaccines; Nucleocapsids; Peptides; Proteins; SARS‐CoV‐2; Serology; Severe acute respiratory syndrome coronavirus 2; Short Communication; Vaccination; Vaccines; antibodies; COVID‐19; SARS‐CoV‐2; cellular immunity; cross‐reactivity; mRNA vaccine

Antibody response to the first dose of BNT162b2 SARS-CoV-2 is greater in COVID-19-convalescent than in infection-naïve individuals. However, there are no data about T-cell response in individuals with pre-existing cellular immunity. We evaluated T-cell responses in parallel with SARS-CoV-2 antibody...